fortyseveninc.com
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
-Forty Seven Inc.’s CD47 antibody to be evaluated in combination with PD-L1 antibody with the aim of engaging both T-cell and macrophage components of the immune system against acute myeloid leukemia and bladder cancer-
MENLO PARK, January 11, 2018 – Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable patient’s immune systems to defeat their cancer, today announced an agreement with Genentech Inc., a member of the Roche Group., for Genentech to sponsor two clinical trials combining Forty Seven’s CD47 antibody, Hu5F9-G4, with Genentech’s PD-L1 antibody, atezolizumab (TECENTRIQ®), in patients with acute myeloid leukemia (AML) and with urothelial (bladder) cancer.
(snip)
Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven Inc.'s CD47 antibody to be evaluated in combination with avelumab
MENLO PARK, November 11, 2017 - Forty Seven Inc. a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable a patient's immune system to defeat their cancer, today announced an agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase 1b clinical trial combining Hu5F9-G4 with avelumab* in patients with ovarian cancer.
(snip) |
